|1.||David, A: 11 articles (01/2007 - 01/2000)|
|2.||Quraishi, S: 9 articles (01/2005 - 01/2000)|
|3.||Adams, C E: 4 articles (01/2007 - 01/2000)|
|4.||Adams, Clive E: 3 articles (01/2015 - 01/2011)|
|5.||Purgato, Marianna: 2 articles (01/2012 - 01/2011)|
|6.||Biermasz, Nienke R: 2 articles (11/2005 - 03/2003)|
|7.||Roelfsema, Ferdinand: 2 articles (11/2005 - 03/2003)|
|8.||Romijn, Johannes A: 2 articles (11/2005 - 03/2003)|
|9.||Rathbone, J: 2 articles (01/2005 - 01/2005)|
|10.||Quraishi, S N: 2 articles (01/2004 - 01/2004)|
|1.||Parkinson Disease (Parkinson's Disease)
01/01/1992 - "Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. "
01/01/1995 - "[Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations]."
10/30/1991 - "[Treatment of Parkinson disease with levodopa depot preparations]."
01/01/1986 - "Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations."
01/01/1987 - "The efficacy of a novel oral sustained-release preparation of L-dopa (Madopar HBS) was compared to that of previous standard L-dopa treatment in 10 patients with idiopathic Parkinson's disease and severe fluctuations in motor performance in an open inpatient trial. "
04/01/1999 - "The clinical efficacy of a combined immediate-release and sustained-release preparation of isosorbide-5-mononitrate for angina pectoris is observed within a few minutes of administration. "
09/01/1989 - "Twenty-four patients with severe stable angina pectoris were included in a randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of a controlled-release preparation of isosorbide-5-mononitrate (ISMN-CR) 60 mg once daily or twice daily as adjunctive treatment to a beta blocker. "
01/01/1989 - "The efficacy of a sustained-release preparation of verapamil (verapamil-SR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations. "
01/01/1980 - "The antianginal action of a sustained-release preparation of isosorbide dinitrate (SUS-ID), administered twice a day, was examined in open trial in 61 patients with angina pectoris. "
02/01/1987 - "The effectiveness of a sustained-release preparation of verapamil (verapamil-SR) was compared with the regular formulation of verapamil and with placebo in 12 patients with chronic stable angina pectoris. "
01/01/2014 - "To address the problem of noncompliance, numerous studies have been carried out, involving: sustained-release preparations, prolonged half-life derivatives, new injectors that cause less pain, and other noninvasive delivery methods such as intranasal, pulmonary and transdermal deliveries. "
01/01/2015 - "It is a sustained release preparation of bupivacaine that has been shown to provide pain relief for up to 72 hours with a single local administration. "
02/01/1996 - "1. The aim of this study was to investigate the analgesic effect and its duration of a new sustained-release preparation of tramadol in an experimental pain model based on pain-related chemosomatosensory evoked potentials (CSSEPs) and subjective intensity estimates of painful phasic and tonic stimuli. "
02/01/1996 - "Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain."
10/01/1994 - "Morphine remains the drug of choice for chronic pain when administered in a sustained release preparation. "
06/01/1994 - "Their main role remains as maintenance therapy for ulcerative colitis, but relatively high doses of controlled-release preparations benefit patients with ileal Crohn's disease, following resection, or those who have recently relapsed. "
11/01/1982 - "The sustained-release preparation studied provides sufficient amounts of 5-aminosalicylic acid to all parts of the gut and its curative effect in ulcerative colitis and Crohn's disease should be examined in controlled trials."
04/01/1996 - "1. A controlled-release preparation of mesalazine microgranules (PentasaR; Ferring AS, Vanlose, Denmark) releases the active ingredient over a wide area from the small intestine to the rectum and is consequently expected to bring about therapeutic benefits to patients with ulcerative colitis and Crohn's disease. "
01/01/2002 - "Methylprednisolone acetate as a depot preparation and oral prednisolone are equally effective in inducing remission in patients with moderately active ulcerative colitis. "
08/01/1994 - "Delivery of 5-aminosalicylic acid to the colon by sulphasalazine, other azo-bonded compounds and controlled-release preparations is introduced in the context of metabolism by epithelial cells and therapeutic efficacy in ulcerative colitis. "
07/01/2015 - "Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. "
09/01/2002 - "Our animal tests indicate strong potential for the development and testing of long-acting depot preparations of GnRH antagonists in treating precocious puberty."
01/01/2002 - "The efficacy of a 3-month depot preparation of the GnRH agonist leuprorelin acetate in central precocious puberty was studied. "
01/01/1993 - "Changes in growth hormone-binding protein in girls with central precocious puberty treated with a depot preparation of luteinizing hormone-releasing hormone analogue."
02/01/1990 - "A total of 82 patients (74 girls, 8 boys) are presently participating in an international multicentre trial for treatment of central precocious puberty (CPP) with a slow release gonadotropin-releasing hormone (GnRH) agonist depot preparation: Decapeptyl-Depot (DD). "
|1.||Levodopa (L Dopa)
|2.||Gonadotropin-Releasing Hormone (GnRH)
|3.||levodopa drug combination benserazide
|3.||Drug Therapy (Chemotherapy)